The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes
The move opens Japan’s advanced life science market to Epigenica’s high-throughput epigenetic profiling kits
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
Marks significant milestone for breakthrough biologic to treat rare blood cancers
The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Subscribe To Our Newsletter & Stay Updated
